A Randomized, Open-label, Phase II, Multi-center Trial of Gemcitabine (G) With Pazopanib (P) or Gemcitabine (G) With Docetaxel (T) in Previously Treated Subjects With Advanced Soft Tissue Sarcoma

Trial Profile

A Randomized, Open-label, Phase II, Multi-center Trial of Gemcitabine (G) With Pazopanib (P) or Gemcitabine (G) With Docetaxel (T) in Previously Treated Subjects With Advanced Soft Tissue Sarcoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Pazopanib (Primary) ; Docetaxel; Gemcitabine
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Sep 2017 Planned End Date changed from 1 Dec 2017 to 1 Apr 2018.
    • 29 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 2 Mar 2018.
    • 29 Sep 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top